Sponsored by Tenaya Therapeutics, this program offers genetic testing and counseling at no cost for adults 18-65 years of age, with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) who have a functional implantable cardioverter-defibrillator (ICD) and remain symptomatic despite current therapies. The program analyzes a panel of 17 genes known to be associated with ARVC, to evaluate for an underlying genetic cause of disease. Up to 50-60% of all ARVC cases are due to variants in genes that encode desmosomal proteins that support mechanical and electrical functions of the heart. In particular, variants in the PKP2 gene are reported to account for the majority of genetic causes of ARVC. This program is available within the United States and the test must be ordered by a qualified healthcare provider.
Ensure your patients have options to access genetic testing through our new genetic testing program.
– 1 in 5 patients with a suspected genetic cardiomyopathy or arrhythmia have a positive genetic test result.1 – 2 in 3 of those positive results confer clinical management implications, including targeted therapy or increased risk.1 – ~11% of patients who may have been missed using condition-specific panels were captured with comprehensive testing (like that featured in the Invitae Unlock™ program).2
In partnership with Ionis Pharmaceuticals, this program provides no-cost genetic testing for familial chylomicronemia syndrome (FCS), a genetic condition which is characterized by high plasma triglyceride levels resulting from improper breakdown of chylomicron lipoproteins by the LPL enzyme. No-cost FCS testing is available for patients with a clinical diagnosis of FCS and is being offered to residents of the US and Canada who meet testing eligibility criteria. The test must be ordered by a qualified healthcare professional.
Arrowhead Pharmaceuticals is partnering with Ambry Genetics to provide a sponsored, no-cost genetic testing program (FCS Seek) for patients who have a clinical history of severe hypertriglyceridemia. Patients who are eligible for this program may have an underlying genetic cause of their complications, such as Familial Chylomicronemia Syndrome or hyperlipoproteinemia.
